LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the strengthening of the Company’s
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
… ProQR to Present Results from Phase 1/2 Trial of QR-421a for … & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … “Investors and Media” section of the Company’s website, www.ProQR.com . The dial-in details for the call are +1 …